A recent combined analysis of 2 phase 2 studies indicates that disitamab vedotin (DV) has promising efficacy and a manageable safety profile in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic urothelial carcinoma (UC) who had progressed on at least 1 line of prior systemic chemotherapy. The analysis was published in the Journal of Clinical Oncology. ...
Advanced Urothelial Carcinoma
Advertisement
Latest News
The FDA is granting a priority review for EV/pembro as well as nivo/chemo for the treatment of patients with la/mUC.
Dr. Nizam provides an overview of her recent research on biomarkers of TRAEs associated with EV for aUC.
The panel shares their hopes for the future of bladder cancer treatment.
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
The panel shares treatment sequencing decisions based on a few patient scenarios.
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.
Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Advertisement
Section Editor
Vadim Koshkin, MDGenitourinary Medical Oncologist | University of California, San Francisco
Advertisement
Trending
The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.
